{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:47:55Z","timestamp":1772066875289,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Medical and Health Science and Technology Project","award":["2023KY1126"],"award-info":[{"award-number":["2023KY1126"]}]},{"name":"Zhejiang Traditional Chinese Medicine Science and Technology Project","award":["2023ZL668"],"award-info":[{"award-number":["2023ZL668"]}]},{"name":"Suzhou Clinical Medical Center for Mood Disorders","award":["Szlcyxzx202109"],"award-info":[{"award-number":["Szlcyxzx202109"]}]},{"name":"Suzhou Key Laboratory","award":["SZS2024016"],"award-info":[{"award-number":["SZS2024016"]}]},{"name":"Multicenter Clinical Research on Major Diseases in Suzhou","award":["DZXYJ202413"],"award-info":[{"award-number":["DZXYJ202413"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-07173-9","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:05:40Z","timestamp":1753437940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relationship between cognitive functions and serum neurotrophic factor levels in long-term hospitalized male patients with schizophrenia"],"prefix":"10.1186","volume":"25","author":[{"given":"Pan","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaozhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"7173_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2023.173554","author":"KY Huang","year":"2023","unstructured":"Huang KY, Huang YJ, Chen SJ, et al. The associations between cognitive functions and TSNAX genetic variations in patients with schizophrenia. Pharmacol Biochem Behav. 2023. https:\/\/doi.org\/10.1016\/j.pbb.2023.173554.","journal-title":"Pharmacol Biochem Behav"},{"issue":"18","key":"7173_CR2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","volume":"381","author":"SR Marder","year":"2019","unstructured":"Marder SR, Cannon TD, Schizophrenia. N ENGL J MED. 2019;381(18):1753\u201361.","journal-title":"N ENGL J MED"},{"key":"7173_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01949-9","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023. https:\/\/doi.org\/10.1038\/s41380-023-01949-9.","journal-title":"Mol Psychiatry"},{"key":"7173_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.06.031","author":"B Kanchanatawan","year":"2017","unstructured":"Kanchanatawan B, Thika S, Anderson G, et al. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Progress Neuropsychopharmacol Biol Psychiatry. 201710.1016\/ j.pnpbp.2017.06.031.","journal-title":"Progress Neuropsychopharmacol Biol Psychiatry"},{"key":"7173_CR5","doi-asserted-by":"publisher","unstructured":"Chu AOK, Chang WC, Chan SKW, et al. Comparison of cognitive functions between first-episode schizophrenia patients, their unaffected siblings and individuals at clinical high-risk for psychosis. Psychol Med. 2018;1\u20138. https:\/\/doi.org\/10.1017\/S0033291718002726.","DOI":"10.1017\/S0033291718002726"},{"key":"7173_CR6","doi-asserted-by":"publisher","unstructured":"Fagerlund B, Pantelis C, Jepsen JRM, et al. Differential effects of age at illness onset on verbal memory functions in antipsychoticna\u00efve schizophrenia patients aged 12\u201343 years. Psychol Med. 2020;1\u201311. https:\/\/doi.org\/10.1017\/S0033291720000409.","DOI":"10.1017\/S0033291720000409"},{"key":"7173_CR7","doi-asserted-by":"publisher","first-page":"110867","DOI":"10.1016\/j.pnpbp.2023.110867","volume":"128","author":"Z Li","year":"2024","unstructured":"Li Z, Kang Z, Xia X, et al. Associations of resilience, white matter topological organization, and cognitive functions in first-episode, drug-na\u00efve schizophrenia patients: A moderated mediation analysis. Progress Neuropsychopharmacol Biol Psychiatry. 2024;128:110867.","journal-title":"Progress Neuropsychopharmacol Biol Psychiatry"},{"key":"7173_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/09602011.2017.1409639","author":"A Katsumi","year":"2017","unstructured":"Katsumi A, Hoshino H, Fujimoto S, et al. Effects of cognitive remediation on cognitive and social functions in individuals with schizophrenia. Neuropsychological Rehabilitation. 2017. https:\/\/doi.org\/10.1080\/09602011.2017.1409639.","journal-title":"Neuropsychological Rehabilitation"},{"key":"7173_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/2013.jamapsychiatry.43","volume":"70","author":"JH MacCabe","year":"2013","unstructured":"MacCabe JH, Wicks S, L\u00f6fving S, et al. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. JAMA Psychiatry. 2013;70:261\u201370.","journal-title":"JAMA Psychiatry"},{"key":"7173_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12325-012-0001-4","volume":"29","author":"H Kitchen","year":"2012","unstructured":"Kitchen H, Rofail D, Heron L, et al. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012;29:148\u201362.","journal-title":"Adv Ther"},{"key":"7173_CR11","doi-asserted-by":"publisher","first-page":"100233","DOI":"10.1016\/j.scog.2021.100233","volume":"28","author":"A Kadakia","year":"2022","unstructured":"Kadakia A, Fan Q, Shepherd J, et al. Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia. Schizophr Res Cogn. 2022;28:100233.","journal-title":"Schizophr Res Cogn"},{"issue":"3","key":"7173_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neubiorev.2010.07.001","volume":"35","author":"AK Fett","year":"2011","unstructured":"Fett AK, Viechtbauer W, Dominguez MD, et al. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35(3):573\u201388.","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"7173_CR13","first-page":"546","volume":"43","author":"J Firth","year":"2017","unstructured":"Firth J, Stubbs B, Rosenbaum S, et al. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2017;43(3):546\u201356.","journal-title":"Schizophr Bull"},{"issue":"1","key":"7173_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/ern.09.143","volume":"10","author":"SK Hill","year":"2010","unstructured":"Hill SK, Bishop JR, Palumbo D, et al. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010;10(1):43\u201357.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"7173_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1101\/lm.54603","volume":"10","author":"B Lu","year":"2003","unstructured":"Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem. 2003;10(2):86\u201398.","journal-title":"Learn Mem"},{"issue":"4","key":"7173_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1017\/S1461145709991015","volume":"13","author":"A Pillai","year":"2010","unstructured":"Pillai A, Kale A, Joshi S, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol. 2010;13(4):535\u20139.","journal-title":"Int J Neuropsychopharmacol"},{"key":"7173_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5498\/wjp.v6.i1.84","volume":"6","author":"M Serra-Mill\u00e0s","year":"2016","unstructured":"Serra-Mill\u00e0s M. Are the changes in the peripheral Brain-Derived neurotrophic factor levels due to platelet activation?? World J Psychiatry. 2016;6:84\u2013101.","journal-title":"World J Psychiatry"},{"key":"7173_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neulet.2014.05.034","volume":"575","author":"T Niitsu","year":"2014","unstructured":"Niitsu T, Shirayama Y, Matsuzawa D, et al. Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia. Neurosci Lett. 2014;575:37\u201341.","journal-title":"Neurosci Lett"},{"key":"7173_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/s12888-021-03578-4","volume":"21","author":"BA Turkmen","year":"2021","unstructured":"Turkmen BA, Yazici E, Erdogan DG, et al. BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia. BMC Psychiatry. 2021;21:562.","journal-title":"BMC Psychiatry"},{"key":"7173_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby167","author":"HK Hamilton","year":"2018","unstructured":"Hamilton HK, Woods SW, Roach BJ, et al. Auditory and visual oddball stimulus processing Deffcits in schizophrenia and the psychosis risk syndrome: forecasting psychosis risk with P300. Schizophr Bull. 2018. https:\/\/doi.org\/10.1093\/schbul\/sby167.","journal-title":"Schizophr Bull"},{"key":"7173_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.biopsych.2020.04.002","volume":"88","author":"HK Hamilton","year":"2020","unstructured":"Hamilton HK, Boos AK, Mathalon DH. Electroencephalography and Event-Related potential biomarkers in individuals at clinical high risk for psychosis. Biol Psychiatry. 2020;88:294\u2013303.","journal-title":"Biol Psychiatry"},{"key":"7173_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.schres.2004.05.023","volume":"74","author":"MF Green","year":"2005","unstructured":"Green MF, Barnes TR, Danion JM, et al. The FOCIS international survey on psychiatrists\u2019 opinions on cognition in schizophrenia. Schizophr Res. 2005;74:253\u201361.","journal-title":"Schizophr Res"},{"key":"7173_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.euroneuro.2013.11.001","volume":"24","author":"W Belgaied","year":"2014","unstructured":"Belgaied W, Samp J, Vimont A, et al. Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder. Eur Neuropsychopharmacol. 2014;24:133\u201341.","journal-title":"Eur Neuropsychopharmacol"},{"key":"7173_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3389\/fpsyt.2020.00731","volume":"11","author":"S Raffard","year":"2020","unstructured":"Raffard S, Lebrun C, Bayard S, et al. Self-awareness deficits of cognitive impairment in individuals with schizophrenia. Really? Frontier Psychiatry. 2020;11:731.","journal-title":"Really? Frontier Psychiatry"},{"key":"7173_CR25","unstructured":"Association AP. Diagnostic and Statistical Manual of Mental Disorders, fifth ed. DSM-5. 2013."},{"key":"7173_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"7173_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.brainresbull.2012.03.005","volume":"88","author":"E Oral","year":"2012","unstructured":"Oral E, Canpolat S, Yildirim S, et al. Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder. Brain Res Bull. 2012;88:454\u20139.","journal-title":"Brain Res Bull"},{"key":"7173_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","volume":"399","author":"S Jauhar","year":"2022","unstructured":"Jauhar S, Johnscone M, Mckenna P. Schizophrenia Lancet. 2022;399:473\u201386.","journal-title":"Schizophrenia Lancet"},{"key":"7173_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.55782\/ane-2015-2037","volume":"75","author":"P Ratajczak","year":"2015","unstructured":"Ratajczak P, Kus K, Murawiecka P, et al. Biochemical and cognitive impairments observed in animal models of schizophrenia induced by prenatal stress paradigm or Methylazoxymethanol acetate administration. Acta Neurobiol Exp. 2015;75:314\u201325.","journal-title":"Acta Neurobiol Exp"},{"key":"7173_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/schbul\/sbu013","volume":"40","author":"JL Reilly","year":"2014","unstructured":"Reilly JL, Sweeney JA. Generalized and specific neurocognitive deficits in psychotic disorders: utility for evaluating Pharmacological treatment effects and as intermediate phenotypes for gene discovery. Schizophr Bull. 2014;40:516\u201322.","journal-title":"Schizophr Bull"},{"key":"7173_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2013.03.001","volume":"32","author":"YZ Xiang","year":"2013","unstructured":"Xiang YZ, Wei T, Mei HX, et al. Interleukin 18 and cognitive impairment in first episode and drug Na\u00efve schizophrenia versus healthy controls. Brain Behav Immun. 2013;32:105\u201311.","journal-title":"Brain Behav Immun"},{"key":"7173_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.pnpbp.2017.03.013","volume":"76","author":"W Xiao","year":"2017","unstructured":"Xiao W, Ye F, Liu C, et al. Cognitive impairment in first-episode drug-na\u00efve patients with schizophrenia: relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. Progress Neuropsychopharmacol Biol Psychiatry. 2017;76:163\u20138.","journal-title":"Progress Neuropsychopharmacol Biol Psychiatry"},{"key":"7173_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3758\/s13415-013-0211-5","volume":"14","author":"JM Sheffeld","year":"2014","unstructured":"Sheffeld JM, Gold JM, Strauss ME, et al. Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn Affect Behav Neurosci. 2014;14:161\u201374.","journal-title":"Cogn Affect Behav Neurosci"},{"key":"7173_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.09.027","author":"NKW Cheuk","year":"2023","unstructured":"Cheuk NKW, Tse W, Tsui HKH, et al. A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia. Schizophr Res. 2023. https:\/\/doi.org\/10.1016\/j.schres.2023.09.027.","journal-title":"Schizophr Res"},{"issue":"5","key":"7173_CR35","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/1469-8986.00070","volume":"40","author":"YW Jeon","year":"2003","unstructured":"Jeon YW, Polich J. Meta-analysis of P300 and schizophrenia: patients,paradigms, andpractical implications. Psychophysiology. 2003;40(5):684\u2013701.","journal-title":"Psychophysiology"},{"issue":"1\u20133","key":"7173_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.schres.2008.01.020","volume":"101","author":"Y Higuchi","year":"2008","unstructured":"Higuchi Y, Sumiyoshi T, Kawasaki Y, et al. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome inpatients with schizophrenia: a LORETA analysis of P300. Schizophr Res. 2008;101(1\u20133):320\u201330.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"7173_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.schres.2009.12.035","volume":"119","author":"RD Jindal","year":"2010","unstructured":"Jindal RD, Pillai AK, Mahadik SP, et al. Decreased BDNF in patients with antipsychotic Naive first episode schizophrenia. Schizophr Res. 2010;119(1\u20133):47\u201351.","journal-title":"Schizophr Res"},{"issue":"9","key":"7173_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.pnpbp.2014.01.012","volume":"51","author":"SL Chen","year":"2014","unstructured":"Chen SL, Lee SY, Chang YH, et al. The BDNF, Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;51(9):99\u2013104.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"7173_CR39","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.pnpbp.2008.04.007","volume":"32","author":"E Rizos","year":"2008","unstructured":"Rizos E, Rontos IE, Arsenis G, et al. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1308\u201311.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"7173_CR40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JCP.0b013e31821895c1","volume":"31","author":"AH Lee","year":"2011","unstructured":"Lee AH, Lange C, Ricken R, et al. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol. 2011;31(3):334\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"7173_CR41","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/mp.2014.117","volume":"20","author":"BS Fernandes","year":"2014","unstructured":"Fernandes BS, Steiner J, Berk M, et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry. 2014;20(9):1108\u201319.","journal-title":"Mol Psychiatry"},{"key":"7173_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2016.11.001","author":"W Xiao","year":"2016","unstructured":"Xiao W, Ye F, Ma L, et al. Atypical antipsychotic treatment increases glial cell line-derived neurotrophic factor serum levels in drug-free schizophrenic patients along with improvement of psychotic symptoms and therapeutic effects. Psychiatry Res. 2016. https:\/\/doi.org\/10.1016\/j.psychres.2016.11.001.","journal-title":"Psychiatry Res"},{"key":"7173_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.eurpsy.2014.11.003","volume":"30","author":"Z Tunca","year":"2015","unstructured":"Tunca Z, Kivircik Akdede B, Ozerdem A, et al. Diverse glial cell line-derived neurotrophic factor (GDNF) support between mania and schizophrenia: a comparative study in four major psychiatric disorders. Eur Psychiatry. 2015;30:198\u2013204.","journal-title":"Eur Psychiatry"},{"issue":"6","key":"7173_CR44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0028-3908(99)00030-1","volume":"38","author":"CC Chao","year":"1999","unstructured":"Chao CC, Lee EH. Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation. Neuropharmacology. 1999;38(6):913\u20136.","journal-title":"Neuropharmacology"},{"issue":"2","key":"7173_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00213-012-2643-y","volume":"222","author":"XY Zhang","year":"2012","unstructured":"Zhang XY, Liang J, Chen da C, et al. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology. 2012;222(2):277\u201384.","journal-title":"Psychopharmacology"},{"issue":"6","key":"7173_CR46","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/sj.mp.4001308","volume":"8","author":"CS Weickert","year":"2003","unstructured":"Weickert CS, Hyde TM, Lipska BK, et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2003;8(6):592\u2013610.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"7173_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0920-9964(00)00084-0","volume":"52","author":"N Durany","year":"2001","unstructured":"Durany N, Michel T, Z\u00f6chling R, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res. 2001;52(1):79\u201386.","journal-title":"Schizophr Res"},{"issue":"4","key":"7173_CR48","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1460-9568.1994.tb00312.x","volume":"6","author":"M Knipper","year":"1994","unstructured":"Knipper M, Da PBM, Bl\u00f6chl A, et al. Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur J Neurosci. 1994;6(4):668\u201371.","journal-title":"Eur J Neurosci"},{"issue":"7","key":"7173_CR49","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1046\/j.0953-816x.2001.01724.x","volume":"14","author":"R Gerlai","year":"2001","unstructured":"Gerlai R, Mcnamara A, Choilundberg DL, et al. Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur J Neurosci. 2001;14(7):1153\u201363.","journal-title":"Eur J Neurosci"},{"key":"7173_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2014.07.045","volume":"274","author":"VS Naumenko","year":"2014","unstructured":"Naumenko VS, Kondaurova EM, Bazovkina DV, et al. Effect of GDNF on depressive-like behavior, Spatial learning and key genes of the brain dopamine system in genetically predisposed to behavioral disorders mouse strains. Behav Brain Res. 2014;274:1\u20139.","journal-title":"Behav Brain Res"},{"issue":"3","key":"7173_CR51","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jad.2011.03.043","volume":"132","author":"X Wang","year":"2011","unstructured":"Wang X, Hou Z, Yuan Y, et al. Association study between plasma GDNF and cognitive function in late-onset depression. J Affect Disord. 2011;132(3):418\u201321.","journal-title":"J Affect Disord"},{"issue":"9","key":"7173_CR52","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.neurobiolaging.2007.02.026","volume":"29","author":"M Pertusa","year":"2008","unstructured":"Pertusa M, Garcia-Matas S, Mammeri H, et al. Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging. 2008;29(9):1366\u201379.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"7173_CR53","first-page":"108","volume":"86","author":"KI Mathis","year":"2012","unstructured":"Mathis KI, Wynn JK, Jahshan C. An electrophysiological investigation of attentional Blink in schizophrenia: separating perceptual and attentional processes. Int J Psychophysiol Official J Int Organ Psychophysiol. 2012;86(1):108\u201313.","journal-title":"Int J Psychophysiol Official J Int Organ Psychophysiol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07173-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:44:19Z","timestamp":1757292259000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07173-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7173"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07173-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that all experiments on human subjects were conducted in accordance with the Declaration of Helsinki and that all procedures were carried out with the adequate understanding and written consent of the subjects. All experimental protocols were approved by the Ethics Committee of WuTaiShan Hospital of Yangzhou University. Informed consent was obtained from all the participants and\/or their legal guardians. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"726"}}